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Abstract
Introduction: Stunting is a key issue for adolescents with perinatally acquired HIV (APH) that needs to be better understood.
As part of the IeDEA multiregional consortium, we described growth evolution during adolescence for APH on antiretroviral
therapy (ART).
Methods: We included data from sub-Saharan Africa, the Asia-Pacific, and the Caribbean, Central and South America regions
collected between 2003 and 2016. Adolescents on ART, reporting perinatally acquired infection or entering HIV care before
10 years of age, with at least one height measurement between 10 and 16 years of age, and followed in care until at least
14 years of age were included. Characteristics at ART initiation and at 10 years of age were compared by sex. Correlates of
growth defined by height-for-age z-scores (HAZ) between ages 10 and 19 years were studied separately for males and
females, using linear mixed models.
Results: Overall, 8737 APH were included, with 46% from Southern Africa. Median age at ART initiation was 8.1 years (in-
terquartile range (IQR) 6.1 to 9.6), 50% were females, and 41% were stunted (HAZ<2 SD) at ART initiation. Males and
females did not differ by age and stunting at ART initiation, CD4 count over time or retention in care. At 10 years of age,
34% of males were stunted versus 39% of females (p < 0.001). Females had better subsequent growth, resulting in a higher
prevalence of stunting for males compared to females by age 15 (48% vs. 25%) and 18 years (31% vs. 15%). In linear mixed
models, older age at ART initiation and low CD4 count were associated with poor growth over time (p < 0.001). Those
stunted at 10 years of age or at ART initiation had the greatest growth improvement during adolescence.
Conclusions: Prevalence of stunting is high among APH worldwide. Substantial sex-based differences in growth evolution dur-
ing adolescence were observed in this global cohort, which were not explained by differences in age of access to HIV care,
degree of immunosuppression or region. Other factors influencing growth differences in APH, such as differences in pubertal
development, should be better documented, to guide further research and inform interventions to optimize growth and health
outcomes among APH.
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1 | INTRODUCTION
Adolescence, defined by the World Health Organization
(WHO) as between 10 and 19 years of age [1], is a critical
transition period in life, accompanied by significant biological
and psychosocial changes [2]. In the context of HIV, major
improvements in access to antiretroviral therapy (ART) for
children with perinatally acquired HIV infection have led to
reductions in HIV-related mortality, resulting in a growing
population of adolescents living with perinatally acquired HIV
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(APH). In 2016, it was estimated that 2.1 million adolescents
were living with HIV worldwide, with 80% in sub-Saharan
Africa [3]. AIDS-related deaths are one of the leading causes
of mortality among adolescents in this region [4]. Adolescents
living with HIV face specific challenges in terms of HIV care
and outcomes [5], including HIV disclosure issues [6], access
to sexual and reproductive health services [7] and transition
from paediatric to adult care [8]. Adolescents are reported to
have the lowest adherence to ART [9] and high rates of lost-
to-follow-up (LTFU) [10].
Growth deficiency is a key concern for children and adoles-
cents living with HIV [11,12]. There are overlapping effects on
growth resulting from a vicious cycle between malnutrition
and HIV infection. Malnutrition impairs the immune system
and weakens the body’s defences, leading to HIV disease pro-
gression [13]; while HIV infection, related opportunistic infec-
tions and chronic inflammation may weaken nutritional status
[14,15]. Repeated episodes of malnutrition during infancy and
childhood may have occurred frequently among APH, and life-
long HIV infection can lead to chronic malnutrition and growth
retardation as APH age into adulthood. Adolescence is the
second most important period of growth after the first year
of life [16], hence these factors may hinder pubertal growth
spurt for APH. Chronic diseases, malnutrition and HIV infec-
tion during childhood could also delayed puberty, worsening
growth retardation during adolescence for APH [17–20].
While data show that nearly half of adolescents suffer from
stunting in some developing countries [21], data on growth
and stunting are limited among APH. Several studies have
shown that growth improves after ART initiation, with larger
increases for children initiated earlier on ART [22,23], but
most of these studies were conducted among children
younger than 10 years of age or during the first two years on
ART. Little is known about growth during adolescence among
APH and those on long-term ART. As part of the IeDEA
(International epidemiology Databases to Evaluate AIDS) mul-
tiregional consortium, we described growth evolution and its
associated factors during adolescence for males and females
with perinatally acquired HIV.
2 | METHODS
2.1 | Study population
The IeDEA global paediatric collaboration is part of the global
IeDEA research consortium (https://www.iedea.org/), sup-
ported by the US National Institutes of Health since 2006, to
describe HIV epidemiology and evaluate HIV outcomes using
large patient-level observational databases. HIV care cohorts
from sub-Saharan Africa (West, Central, Eastern and Southern
Africa regions), the Asia-Pacific, and the Caribbean, Central
and South America (CCASAnet) regions contributed data for
this analysis. We merged data collected from HIV clinics in
partnership with IeDEA from these six sub-regions between
2003 and 2016. Among patients who had at least one visit
available during adolescence, with at least one height mea-
surement during this period (i.e. age 10 to 19 years), inclusion
criteria to assess growth throughout adolescence were as fol-
lows: reported perinatally acquired infection or entering HIV
care before 10 years of age (proxy for perinatally acquired
HIV when not documented); having a documented date of
ART initiation, at least one height measurement between 10
and 16 years of age; and followed in care until at least
14 years of age. APH were thus excluded if known to have
acquired HIV non-perinatally or if not known, be enrolled in
care after 10 years of age. They were then excluded if no
ART initiation (excluded group A) and no HAZ measurements
between 10 and 16 years of age (excluded group B) were
documented, and if they were not followed after 14 years of
age (excluded group C).
2.2 | Variables and data management
We studied growth using height-for-age, defined by the WHO
child growth standards [24,25], expressed in z-scores (HAZ).
Stunting was defined as HAZ lower than  2 standard devia-
tions (SD), with moderate stunting between  3 and  2 SD
and severe stunting lower than  3 SD. Z-scores lower
than  10 or greater than + 10 were viewed as outliers and
removed. Growth velocity defined as height gain in centimetre
(cm) per year was compared to the reference population from
the WHO child growth standards for a subset of adolescents
having at least two height measurements. We calculated
growth velocity per year by dividing the height gain in cm
between two clinical visits by the time in years between these
two visits. Velocities greater than 20 cm/year and
below  1 cm/year were excluded as outliers. Wasting was
defined using weight-for-height z-score (WHZ) for children
under five years of age, and body-mass-index-for-age z-score
(BAZ) for children aged more than five years. Immunodefi-
ciency for age at ART initiation was defined following the
2006 WHO guidelines [26]. The location of the clinic site (ur-
ban or mostly urban, rural or mostly rural) was also recorded.
Follow-up for patients was analysed on a six-monthly basis,
with data on immunologic, clinical, anthropometric status and
ART regimen collected. Loss to follow-up was defined as hav-
ing a last contact longer than six months before database clo-
sure in children not known to have died or transferred out,
and transfer was documented when adolescents were trans-
ferred to another paediatric clinic or to adult care.
2.3 | Ethics approval
Each participating IeDEA region obtained local institutional
review boards’ approvals to participate. Consent requirements
were deferred to the local institutional review boards. The
analysis only used anonymized data that had been collected as
part of routine clinical care.
2.4 | Statistical analysis
Patient characteristics were described at ART initiation and at
age 10 years, and compared by sex using Chi-square tests for
categorical variables and Kruskal-Wallis tests for continuous
variables. Characteristics of the study population were also
compared to those of excluded adolescents. Prevalence of
stunting was measured at ART initiation and each year
between 10 and 19 years of age, stratified by sex. Mean HAZ,
together with 95% confidence intervals, was plotted stratified
by age and sex.
The analysis and inclusion to the study started at age
10 years (baseline). Growth, modelled as mean HAZ
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between ages 10 and 19 years, was studied using linear
mixed models, with an unstructured variance-covariance
matrix and random intercept. All participants with at least
one HAZ were able to contribute to the model [27]. The
model contained time-varying age (=10 years plus follow-up
time) as a covariate which was included non-linearly using
(penalized) splines [28]. Age at ART initiation, stunting and
wasting at ART initiation and at age 10 years, current CD4
count, CD4 count at age 10 years, CD4 count at ART initi-
ation and at first visit as well as region and location of
clinic site were considered as potential adjustment variables.
To take into account missing data, especially at baseline, we
conducted multiple imputation for stunting and wasting at
age 10 years and ART initiation as well as CD4 count and
location, using the Amelia II package in R [29]. The imputa-
tion model contained all measured variables, as well as
splines of time and lagged variables of CD4 count. Variable
selection using the AIC criteria was applied to the imputed
data sets [30,31]. The final mixed model containing the
selected variables was fitted in all five imputed data sets
and results were combined according to Rubin’s rules [32].
The penalized spline for the association of age with HAZ is
displayed for the first imputed data set (see Figure S1 for
the other imputed data sets).
3 | RESULTS
3.1 | Selection and characteristics of the study
population
Between 2003 and 2016, 68,461 patients receiving care in
the six IeDEA regional cohorts had at least one visit during
adolescence. Of these, 50,469 (74%) had one available HAZ
measurement during the same period, and 21,038 (42%) of
them met criteria for perinatally acquired infection. Among
APH on ART, the majority had at least one available HAZ
measurement between 10 and 16 years of age. The median
age at last follow-up was 14.2 (interquartile range (IQR) 12.1
to 16.5 years), with 43% followed up until at least 14 years of
age. Among the APH excluded for not being followed after
14 years of age, 73% had not yet reached age 14 years by
the time the database was closed. The final study population
included 8737 APH (Figure 1).
APH excluded for three criteria (no information on ART initia-
tion (A), no HAZ measurements between 10 and 16 years of
age (B), no follow-up after 14 years of age (C), Figure 1) were
compared to the final study population. Those from the exclusion
group A (n = 401) were more frequently LTFU (22% vs. 8%) and
less stunted (18% vs. 29%, p < 0.001). The exclusion group B
(n = 334) initiated ART mostly after age 10 years (63% vs. 17%,
p < 0.001), with a higher rate of death (4% vs. 2%, p = 0.003)
and LTFU (39% vs. 8%, p < 0.001). Finally, the exclusion group C
(n = 11,566) was more likely to have started ART below five
years of age compared to the study population (34% vs. 15%,
p < 0.001), they more frequently had missing data for assessing
stunting, wasting and CD4 count at 10 years (p < 0.001) and
had slightly higher rates of LTFU (10% vs. 8%, p < 0.001) but
mortality was similar. The latter group comprised 94% of those
excluded for these three reasons and are mostly children who
had not yet reached the age of 14 years as they had started
ART more recently and at younger ages and could not contribute
to examining growth throughout adolescence (Table S1).
Overall, 50.5% were females, 45.6% were living in Southern
Africa, and 76.7% were followed in an urban or mostly urban
Patients with at least one Height for age Z-score 
(HAZ) available between 10 and 19 years old
N = 50,469, 74%
Patients with perinatally acquired HIV documented 
or enrolled in care before 10 years of age (proxy)
N = 21,038, 42%
Patients on ART, with date of ART initiation available
N = 20,637, 98%
Patients with at least one HAZ available between 10 
and 16 years of age
N = 20,303, 98%
Patients followed at least until 14 years of age 
N = 8,737, 43%
Patients with at least one visit between 10 and 19 
years of age
N = 68,461 (100%)
A) Excluded for not being on ART or not 
having documented date of ART initiation
N = 401, 2%
B) Excluded for not having HAZ available 
between 10 and 16 years
N = 334, 2%
C) Excluded for not being followed up after 
14 years of age 
N = 11,566, 57% 
(94% of A+B+C excluded group)
Excluded for not having any height data 
available during adolescence
N = 17,992, 26%
Excluded for having acquired HIV non 
perinatally or enrolled in care after age 10 
years
N = 29,431, 58%
Figure 1. Flowchart of the study population, IeDEA global paediatric collaboration, 2003 to 2016.
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Table 1. Characteristics at ART initiation and at 10 years of age for males and females, N = 8737, IeDEA global paediatric collabo-
ration, 2003 to 2016
Variables Males (N = 4329) Females (N = 4408) p-valuea Total
Characteristics at ART initiation
Age
Median, IQR (years) 8.0 [6.1 to 9.5] 8.2 [6.2 to 9.6] 0.007 8.1 [6.1 to 9.6]
Age groups 0.186
0 to 2 years 146 3.4 166 3.8 312 3.6
2 to 5 years 527 12.2 488 11.1 1015 11.6
5 to 10 years 2950 68.1 2959 67.1 5909 67.6
>10 years 706 16.3 795 18.0 1501 17.2
CD4 count
Median, IQR (cell/mm3) 294 [130 to 517] 307 [148 to 516] 301 [139 to 516]
Immunodeficiency for ageb 0.148
No 604 13.9 643 14.6 1247 14.3
Moderate 1008 23.3 1087 24.7 2095 24.0
Severe 1598 36.9 1620 36.7 3218 36.8
Missing 1119 25.9 1058 24.0 2177 24.9
HAZ
Median, IQR (z-score) 2.05 [2.95 to 1.16] 1.96 [2.85 to 1.05] 0.020 1.99 [2.90 to 1.11]
Stunting groups 0.101
No stunting 1742 40.2 1873 42.5 3615 41.4
Moderately stunted 949 21.9 974 22.1 1923 22.0
Severely stunted 837 19.3 795 18.0 1632 18.7
Missing 801 18.5 766 17.4 1567 17.9
WHZ/BAZ
Wasting groups 0.010
No wasting 2828 65.3 3010 68.3 5838 66.8
Moderately wasted 362 8.4 346 7.8 708 8.1
Severely wasted 306 7.1 251 5.7 557 6.4
Missing 833 19.2 801 18.2 1634 18.7
Characteristics at 10 years
CD4 count
Median, IQR (cell/mm3) 652 [410 to 920] 674 [434 to 952] 0.008 664 [423 to 938]
CD4 count groups 0.133
<250 297 6.9 272 6.2 569 6.5
>250 2292 52.9 2420 54.9 4712 53.9
Missing 1740 40.2 1716 38.9 3456 39.6
HAZ
Median, IQR (Z-score) 1.59 [2.32 to 0.87] 1.70 [2.48 to 0.90] <0.001 1.64 [2.41 to 0.89]
Stunting groups <0.001
No stunting 2221 51.3 2079 47.2 4300 49.2
Moderately stunted 854 19.7 900 20.4 1754 20.1
Severely stunted 310 7.2 460 10.4 770 8.8
Missing 944 21.8 969 22.0 1913 21.9
WHZ/BAZ
Wasting groups 0.233
No wasting 3109 71.8 3179 72.1 6288 72.0
Moderately wasted 259 6.0 257 5.8 516 5.9
Severely wasted 122 2.8 95 2.2 217 2.5
Missing 839 19.4 877 19.9 1716 19.6
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clinical care centre. Median age at ART initiation was
8.1 years (IQR 6.1 to 9.6), with 84.8% initiating ART after age
five years. The prevalence of stunting at ART initiation was
49.6% among those with available HAZ measurement
(n = 6560); of these, 45.9% were severely stunted. Among
those with available WHZ/BAZ data (n = 7103), 18% were
wasted at ART initiation and 10% at age 10 years. Overall,
characteristics at ART initiation did not differ by sex, with sim-
ilar age groups (p = 0.186), CD4 count (p = 0.063) and stunt-
ing (p = 0.101). Males were slightly more wasted than females
at ART initiation (p = 0.010). The absolute differences in med-
ian age at ART initiation (males vs. females: 8.02 vs. 8.19,
p = 0.007) and median HAZ (males vs. females: 2.05 vs.
1.96, p = 0.020) were minimal (Table 1). At age 10 years,
the prevalence of stunting was 34.4% among males and
39.5% among females (p < 0.001), with about one-third
severely stunted in each group. There were no observed dif-
ferences by sex in CD4 count groups or the severity of wast-
ing (Table 1).
Median number of height measurements was 21 (IQR 11 to
33). Males and females had similar retention, with a median
age at enrolment (clinic entry) of 7.1 years (IQR 5.1 to 8.6,
p = 0.425) and median age at last visit of 16.1 years (IQR
14.9 to 17.7, p = 0.160); 16.7% were transferred (p = 0.435),
7.6% were LTFU (p = 0.966) and 1.9% died during adoles-
cence (p = 0.283) (data not shown).
3.2 | Growth development during adolescence
3.2.1 | Growth velocity curves
In patients with at least two height measurements (n = 6397),
growth velocity during adolescence was highest at age
13 years for APH males (mean value: 7.2 cm per year) while
the peak growth velocity was reached at age 11 for APH
females (mean value: 6.4 cm per year). Overall, growth veloc-
ity among males was similar to the reference population at
age 10 but then diverged with relative reductions among APH
until age 15 (mean value at age 13 years: 5.5 cm per year).
After this period, while growth velocity for the reference pop-
ulation decreased, it stayed at a higher level for APH through-
out late adolescence (mean values: 4.7 vs. 3.5 cm per year at
16 years, 1.9 vs. 0.3 cm per years at 19 years). For females,
growth velocity was slightly lower than reference values for
APH until age 12 years (mean value at 11 years: 6.1 cm per
year) and then stayed consistently higher (means values: 3.2
vs. 1.6 cm per year at 15 years, 1.7 vs. 0.3 cm per year at
17 years, 1.2 vs. 0.1 cm per year at 19 years) (Figure 2).
3.2.2 | Prevalence of stunting and HAZ curves
HAZ evolution during adolescence differed by sex and was in
line with the deviations observed in growth velocity. For
males, the growth deficit observed in early adolescence
resulted in a decrease of mean HAZ between 10 and
14 years of age (mean values: 1.6 SD at 10 years, 2.1 SD
at 14 years), followed by a constant increase until age
19 years, reaching similar values to those at age 10 (mean
value: 1.43 SD at 19 years). For females, mean HAZ
increased continuously during adolescence, especially after
age 12 years (mean values: 1.7 SD at 12 years, 1.3 SD at
15 years, 1.0 SD at 19 years). HAZ was higher for females
than males after age 12 years, leading to a higher prevalence
of stunting for males (51% vs. 35% at 13 years, p < 0.001;
31% vs. 15% at 18 years, p < 0.001) (Figure 3, left-hand side).
The imputed mixed model resulted in adjusted HAZ estimates
close to the crude values (Figure 3, right-hand side). Trends in
growth evolution by sex were similar by region (Figure S2).
3.2.3 | Factors associated with HAZ evolution
Multivariable imputed linear mixed models are shown in
Table 2. Most of the factors associated with HAZ evolution
were common for both males and females. Older age at ART
initiation was associated with a lower mean HAZ over time
(example for males: mean difference of 0.149 SD for each
year over time, p < 0.001). Higher CD4 count over time was
associated with higher HAZ (example for females: +0.019 SD
Table 1. (Continued)
Variables Males (N = 4329) Females (N = 4408) p-valuea Total
Context
Location of clinical centres
Urban or mostly urban 3321 76.7 3438 78.0 0.121 6759 77.4
Rural or mostly rural 947 21.9 895 20.3 1842 21.1
Missing 61 1.4 75 1.7 136 1.6
Regions 0.022
West Africa 361 8.3 345 7.8 706 8.1
Central Africa 200 4.6 200 4.5 400 4.6
East Africa 741 17.1 752 17.1 1493 17.1
Southern Africa 2028 46.9 1956 44.4 3984 45.6
Asia-Pacific 724 16.7 817 18.5 1541 17.6
CCASAnet 275 6.4 338 7.7 613 7.0
BAZ, BMI-for-Age Z-score, WHO Child Growth Standards; HAZ, Height-for-Age Z-score; IQR, interquartile range; WHZ, Weight-for-Height Z-
score.
aComparison tests between males and females using chi square and Kruskal-Wallis tests.; bWHO 2006 guidelines.
Jesson J et al. Journal of the International AIDS Society 2019, 22:e25412
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25412/full | https://doi.org/10.1002/jia2.25412
5














Figure 2. Mean height gain in cm per year for males (left) and females (right) during adolescence (dashed line), compared to the reference
population of the WHO child growth standards (solid line).
IeDEA global paediatric collaboration, 2003 to 2016.
Figure 3. Mean Height-for-Age Z-score (HAZ) evolution during adolescence with sample size and prevalence of stunting at each age
(N = 8737).
Crude results (left) and adjusted estimates of the first imputed mixed model (right) using the following reference population: ART start at age 5,
current CD4 = 100, CD4 at age 10 = 100, not rural, moderate stunting at age 10 and ART start, region Asia-Pacific. IeDEA global paediatric col-
laboration, 2003 to 2016.
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per 100 cells/mm3). Those with moderate or severe stunting
at ART initiation had lower mean HAZ at baseline (p < 0.001)
but also higher HAZ increase between 10 and 19 years of
age compared to those not stunted (p < 0.001). For males,
growth evolution also depended on CD4 count at baseline
(+0.003 SD per 100 cells/mm3 over time). Males who were
followed in rural HIV clinic centres had lower HAZ increase
compared to those followed in urban centers (0.047 SD per
year, p < 0.001), while mean HAZ was similar at 10 years of
age (p = 0.289).
4 | DISCUSSION
Growth retardation represents a major concern for APH in
IeDEA cohorts; half of APH were stunted at ART initiation,
and the prevalence of stunting remained high during adoles-
cence. While males and females had similar baseline and fol-
low-up characteristics, their growth patterns during
adolescence diverged considerably. Despite males experiencing
greater height gains later in adolescence, these were not suffi-
cient to compensate for the smaller than expected height
gains in early adolescence, resulting in persistently high rates
of stunting until 19 years of age. Females had substantial
height gains in mid- to late adolescence, above the population
reference, allowing them to have a slow but constant HAZ
increase throughout adolescence; resulting in a much lower
prevalence of stunting by 19 years of age.
Few studies on growth have been conducted among APH,
most of them focusing on the first years of ART [17]. Some
cross-sectional studies have described stunting among
adolescents with HIV. In West and Central Africa, among an
ART-treated population, the prevalence of stunting was 34%
among patients aged 10 to 19 years [33] and 42% among
patients aged 10 to 16 years in Senegal [34]. In El Salvador,
48% of children with HIV over 12 years of age were stunted
[35]. In the Collaborative Initiative for Paediatric HIV Educa-
tion and Research (CIPHER) including cohorts of APH from
IeDEA and other networks in low-, middle- and high-income
countries, median HAZ at ART initiation and at 10 years of
age were similar to our study; however, APH living in high-in-
come countries had higher HAZ than in low-and-middle-in-
come countries (LMICs) [36].
In our cohort, late age at ART initiation was strongly associ-
ated with stunting and poor HAZ evolution. This finding has
been observed in many other studies, but mostly among chil-
dren younger than age 10 years [22,23]. Children who spend
their first years of life with HIV without ART may have
chronic inflammation due to uncontrolled HIV, which can
affect growth. The longer this exposure to uncontrolled HIV,
the more adversely growth might be affected. Repeated
opportunistic infections like pneumonia, chronic diarrhoea and
tuberculosis during this period can also result in stunting. It is
concerning that despite the WHO recommendations for
immediate ART initiation, age at ART initiation was high,
approximately a year later than age at enrolment. This popula-
tion likely had poor access to ART, as already highlighted by
the IeDEA collaboration [37]. While reasons for delayed ART
initiation should be examined, most of these children would
have first enrolled before the WHO recommendation for
immediate ART in all children < 15 years of age, and hence
would have had to meet disease severity or CD4 criteria




















HAZ at age 10
or over time
Age at ART initiation (years) 0.149 (0.019) <0.001 0.113 (0.017) <0.001
Current CD4 count
(per 100 cells/mm3)
0.014 (0.001) <0.001 0.019 (0.004) 0.004
CD4 count at 10 years
(per 100 cells/mm3)
0.003 (0.001) 0.005 – –
Stunting at ART initiation
Moderate versus no 0.322 (0.022) <0.001 0.018 (0.038) <0.001 0.307 (0.024) <0.001 0.023 (0.003) <0.001
Severe versus no 0.229 (0.018) <0.001 0.013 (0.002) <0.001 0.255 (0.018) <0.001 0.013 (0.002) <0.001
Stunting at 10 years of age
Moderate versus no 0.543 (0.028) <0.001 0.007 (0.009) <0.001 0.909 (0.023) <0.001 0.127 (0.003) <0.001
Severe versus no 0.306 (0.018) <0.001 0.007 (0.006) 0.234 0.639 (0.021) <0.001 0.088 (0.002) <0.001
Located in rural versus
urban area
0.059 (0.045) 0.289 0.047 (0.003) <0.001 0.010 (3.831) 0.795 – –
Moderate stunting = (3; 2 (SD, Severe stunting <3 SD)). Multivariable linear mixed models. N = 8737, IeDEA global paediatric collaboration,
2003 to 2016. Adjusted on IeDEA regions. Interaction with time was added for the variables “stunting” for both males and females and location
for males. Difference in estimates were thus expressed in mean HAZ at baseline (10 years of age) and in yearly mean HAZ increase (second col-
umn) for these variables. The other variables (age at ART initiation, current CD4 count and CD4 count at 10 years for both males and females
and location for females) were expressed in difference in estimates over time (first column). Estimates for time variables: Males: t = 0.203,
t2 = 0.014, t3 = 0.001; females: t = 0.149, t2 = 0.053, t3 = 0.004.
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before initiating ART. With better access to paediatric care
and earlier ART initiation than during the study period for
children living with HIV, we could expect to observe lower
rates of stunting at ART initiation and better catch-up growth
during adolescence in the future, decreasing the burden of
stunting for APH. However, stunting is still highly prevalent in
most of the study settings in the general population and
access to early ART initiation is not yet a reality in some sub-
regions such as in West and Central Africa.
Similarly, adolescents with low CD4 count over time had
poorer growth in our cohort. Even on ART, chronic immunod-
eficiency could alter growth [13]. We observed a trend of
poorer growth evolution among males attending rural clinics,
which suggests higher vulnerability of APH living in rural set-
tings that could be related to poverty and food access as well
as the general challenges of ART adherence and retention in
HIV care observed during adolescence [37].
The growth differences observed between males and
females in this study were not fully explained by the available
data. The pubertal development of APH could be different for
males and females and have varying effects on growth, but
the literature on this topic is scarce [17,19,38], especially in
LMICs [18]. In the US, compared to HIV-exposed but unin-
fected adolescents, APH had delayed pubertal onset, from six
to eight months later in females and 10 to 11 months later in
males. In that study, however, the mean HAZ value was nor-
mal and there were no apparent links between pubertal devel-
opment and low HAZ [17]. Ugandan and Zimbabwean APH
have been reported to have substantial pubertal delays, more
pronounced for those who were stunted and initiated ART
late, but similar between males and females, although males
faced more height disadvantage throughout adolescence, as in
our study [18].
Another possible explanation for the growth differences by
sex was found in a US study where APH males had lower
bone mineral density (BMD) compared to males without HIV
in late puberty, while there were no differences for females.
However, there were no height differences between those
with and without HIV in this study [39]. To the best of our
knowledge, the effect of BMD on growth among adolescents
living in LMICs has not been explored [40].
Delayed pubertal onset is also observed in the general pop-
ulation in LMICs [41], and may reflect poor nutrition during
the first 1000 days of life and in later childhood [42], which is
often the case for children with HIV [22]. In rural villages of
The Gambia, HAZ evolution was described from birth to
30 years and showed similar patterns to our study, with an
apparent decline at the start of adolescence, especially for
males, which could be explained by high rates of stunting dur-
ing infancy and a later entry into puberty compared to the
UK reference population [43]. Without further data on the
timing of puberty onset and hormonal pathways in children
with HIV, it is difficult to determine the links and the causal
relationships between delayed pubertal onset and growth
retardation during adolescence, for males and females.
The trajectory of growth evolution was similar across the
IeDEA regions, with differences between males and females.
The hypothesis that in some socio-economic and cultural con-
texts males could be disadvantaged compared to females
regarding nutrition and access to food is therefore unlikely to
explain our results. Nutritional habits among adolescents are
however insufficiently documented in the general population
in our contexts, and even less well documented for adoles-
cents with HIV [43].
Our study has some limitations. Besides lacking puberty
data like Tanner staging or age at first menstruation, we also
did not have detailed anthropometric data around birth and
the first 1000 days of life to explain some aspects of future
growth [21]. There were insufficient data on HIV viral load to
assess the potential association with HAZ. A study in Bots-
wana showed that severe short stature among children and
adolescents with HIV was associated with virologic failure
[44]. In a review on growth after ART initiation among chil-
dren, the ART regimen used was not associated with growth
evolution [22]. Also, pregnancy data were not recorded in all
regions and then not included. Metabolic data were also not
available, but would have been valuable to better assess the
effect of long-term ART on growth [45,46]
Our results could have been affected by selection bias, as
they were driven by the large proportion of children from
Southern Africa, which may not be representative of growth
among APH worldwide. Excluding children who were not fol-
lowed-up until at least 14 years of age substantially restricted
our sample size and adolescents who were LTFU or died
before age 14 were not included, leading to survivor bias, with
the risk of underestimating the prevalence of stunting in this
population. Indeed, some studies tracing children after being
LTFU have shown that this population was at higher risk of
being severely immunodeficient and malnourished [47,48].
Furthermore, perinatal infection was defined using a threshold
of enrolment in HIV care before age 10 years as a proxy,
which excludes the subset of APH who may enter care after
age 10 years and would be at even higher risk of stunting
due to the delay in diagnosis, HIV care and ART initiation.
Thus, the growth pattern described here may underestimate
the full extent of stunting among APH.
We did not analyse outcomes beyond 19 years of age in
order to focus on the period of adolescence. Additional height
gains after age 19 might be expected, and thus this analysis
might have concluded before we knew the final height attain-
ments of all patients included. In rural non-HIV populations in
the Gambia, similar to our results, growth continued in late
adolescence, and extended to the age of 22 to 24 years in
males and 18 to 19 years in girls [43]. This could be due to
population-level maturational delays, caused by delayed pub-
erty onset, allowing stunted children and adolescents to
catch-up on their growth by prolonging pubertal growth
[43,49], with different timing in males and females [50]. This
mechanism highlights adolescence as a second critical window
for growth after the first year of life, and the opportunity for
catch-up growth in stunted children living in LMICs, regard-
less of HIV status [42].
5 | CONCLUSIONS
This study is, to our knowledge, the first multiregional study
assessing growth among a large sample size of APH in LMICs.
The high burden of stunting we observed could have serious
consequences for social and cognitive development [51].
Overall, APH are a vulnerable group, with multiple and inter-
related HIV-specific and general health needs [52]. While
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males seem even more affected by stunting, it is important to
ensure that all APH receive comprehensive support that
addresses growth beyond childhood and into adolescence.
Improved documentation of growth, nutritional status and
pubertal phase among APH would provide key data to guide
further research and inform interventions to optimize growth
and health outcomes.
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